STAMFORD, CT/ NOVEMBER 3, 2021— Stamford Health, known for its award-winning cardiac care through the Heart & Vascular Institute, has expanded its relationship with Columbia University to offer treatment and expertise from Columbia University Irving Medical Center’s nationally recognized heart surgeons. As a result of this new relationship, five of […]
Other News
First U.S. Patient Enrolled in Cardionomic’s CPNS Pilot Study
Study evaluates safety and performance of endovascular pulmonary nerve stimulation in ADHF MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial U.S. enrollment in their global Cardiac Pulmonary Nerve Stimulation (CPNS) Pilot Study (NCT04814134). The study is evaluating the safety and performance of the CPNS System […]
FDA Clears 12 New XO Cross Microcatheters
12 new hydrophilic-coated micro and support catheters cleared by FDA for broad use in the peripheral vasculature. PARK CITY, Utah, Nov. 2, 2021 /PRNewswire/ — Transit Scientific announced the FDA clearance of new hydrophilic-coated XO Cross Microcatheters for guidewire support, exchange, and contrast media injection in the peripheral vasculature. “The XO Cross devices […]
Cordis Names Muscari President Of The Americas
Matthew Muscari takes the helm of global marketing and American sales as Cordis pursues path of transformation and growth MIAMI LAKES, Fla., Nov. 2, 2021 /PRNewswire/ — Cordis, a global interventional vascular technology company, today announced that Matthew Muscari will assume the role of President of the Americas, heading a leadership team responsible […]
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
– More than 3 million people in the US have severe hypertriglyceridemia – The CORE Phase 3 clinical study further expands Ionis’ late-stage pipeline and is the second Phase 3 clinical study in Ionis’ broad olezarsen development program – Olezarsen is one of Ionis’ wholly owned medicines the company plans […]
VUNO Med®-DeepECG™ Designated as Breakthrough Device
SEOUL, South Korea, Nov. 2, 2021 /PRNewswire/ — South Korean artificial intelligence (AI) developer, VUNO inc. announced that the Korean Ministry of Food and Drug Safety (KFDA) has designated the company’s artificial intelligence-based electrocardiogram (ECG) analysis software VUNO Med®-DeepECG™ as the ministry’s 16th Breakthrough Device. Using deep learning, the software analyzes ECG data […]
Argon Medical Launches Novel Innovations for Portal Vein Access Procedures
FRISCO, Texas, Nov. 2, 2021 /PRNewswire/ — Argon Medical Devices, Inc., a global manufacturer of specialty devices for Interventional Radiology, Vascular Surgery, and Interventional Cardiology, formally announced the launch of two unique portal vein access sets intended for transjugular liver access in diagnostic and interventional procedures. The SCORPION® Portal Vein Access Series addresses […]
TCT 2021: Philips announces new innovations and clinical data supporting the treatment of patients with cardiovascular disease
November 2, 2021 Philips debuts three new solutions in the North American market that will help drive procedural innovation and workflow efficiency, adding to the company’s ecosystem of interventional imaging systems, and diagnostic and therapeutic devices New clinical data presented at TCT 2021: five-year outcomes of iFR-SWEDEHEART trial and new large-scale […]
Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 29, 2021 it granted stock options to purchase an aggregate of 68,550 shares of common stock to 8 new employees, whose employment commenced in October 2021, as a material inducement to […]
Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update
– Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth – – Unprecedented CLEAR Outcomes Study Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 80% MACE Accumulation in October – – U.S. Net Product Revenue […]



